This conference poster presents an all-human cardiotoxicity evaluation model using hiPSC-derived cardiomyocytes (YBLiCardio) to support preclinical drug safety assessment. The cardiomyocytes demonstrated expression of key cardiac markers such as Troponin, Alpha-Actinin, and MLC proteins, confirming their functional maturity and suitability for cardiac research.

Comprehensive characterization including gene expression profiling, flow cytometry, and functional contractility analysis confirmed the physiological relevance of the model. The cells also responded to several reference compounds affecting ion channels and cardiac signaling pathways. Th.ese findings highlight the potential of YBLiCardio cardiomyocytes as a reliable platform for evaluating cardiotoxicity, contractility, and arrhythmia risks during early drug development.